Physiogenex Company Profile

Background

Overview

Physiogenex is a preclinical contract research organization (CRO) specializing in metabolic disorders, including obesity, type 2 diabetes, non-alcoholic steatohepatitis (NASH), fibrosis, dyslipidemia, and cardiovascular complications. Established in 2003 and headquartered near Toulouse, France, the company has over 20 years of experience in providing preclinical in vivo and ex vivo services. Physiogenex develops innovative animal models and employs advanced technologies to evaluate the efficacy of drug candidates targeting metabolic diseases.

Mission and Vision

Physiogenex aims to accelerate the development of new therapies for metabolic disorders by offering reliable and high-quality preclinical studies. The company is committed to reducing the time and cost associated with bringing new treatments to market, thereby improving patient outcomes globally.

Industry Significance

As metabolic diseases continue to rise worldwide, Physiogenex plays a crucial role in the pharmaceutical and biotechnology sectors by providing essential preclinical data that informs drug development processes. Its specialized focus on metabolic disorders positions it as a key partner for companies seeking to develop effective treatments in this area.

Key Strategic Focus

Core Objectives

• Accelerate Drug Development: By providing high-quality preclinical data, Physiogenex aims to shorten the time to market for new therapies targeting metabolic diseases.

• Innovate Animal Models: The company focuses on developing predictive animal models that closely mimic human metabolic conditions, enhancing the relevance and reliability of preclinical studies.

Areas of Specialization

• Metabolic Diseases: Including obesity, type 2 diabetes, NASH, fibrosis, dyslipidemia, and cardiovascular complications.

• Preclinical Services: Offering in vivo and ex vivo assays, as well as consulting services tailored to the specific needs of clients.

Key Technologies Utilized

• Predictive Animal Models: Developed in-house to replicate human metabolic disorders.

• Radio-Tracer Based Experiments: Utilized to generate proof-of-concept efficacy data for drug candidates.

Primary Markets Targeted

• Pharmaceutical Companies: Seeking preclinical data for drug development.

• Biotechnology Firms: In need of specialized preclinical studies for metabolic disease therapies.

• Nutraceutical and Agri-Food Industries: Looking to evaluate the efficacy of their products in metabolic disease contexts.

Financials and Funding

Funding History

Specific details regarding Physiogenex's funding history, total funds raised, and recent funding rounds are not publicly disclosed. The company operates as a privately held entity, and such financial information is typically confidential.

Notable Investors

Information about individual investors or venture capital firms involved with Physiogenex is not publicly available.

Utilization of Capital

While specific details are not disclosed, it is common for companies like Physiogenex to utilize capital for:

• Research and Development: To advance and validate new animal models and technologies.

• Facility Expansion: Enhancing laboratory and operational capabilities.

• Talent Acquisition: Recruiting experts in metabolic diseases and related fields.

Pipeline Development

Key Pipeline Candidates

Physiogenex primarily focuses on providing preclinical services rather than developing its own therapeutic candidates. Its pipeline consists of various animal models and assays used to evaluate the efficacy of clients' drug candidates targeting metabolic diseases.

Stages of Development

• Model Development: Creating and validating new animal models that closely mimic human metabolic conditions.

• Assay Development: Designing and implementing in vivo and ex vivo assays to assess drug efficacy.

Target Conditions

• Obesity and Type 2 Diabetes

• NASH and Fibrosis

• Dyslipidemia

• Cardiovascular Complications

Anticipated Milestones

Physiogenex continually updates and refines its models and assays to meet the evolving needs of the pharmaceutical and biotechnology industries. Specific timelines for new developments are not publicly disclosed.

Technological Platform and Innovation

Proprietary Technologies

• Predictive Animal Models: Developed in-house to replicate human metabolic disorders, enhancing the relevance of preclinical studies.

• Radio-Tracer Based Experiments: Utilized to generate proof-of-concept efficacy data for drug candidates.

Significant Scientific Methods

• In Vivo and Ex Vivo Assays: Comprehensive testing platforms to evaluate drug efficacy and mechanisms of action.

• Diet-Induced Animal Models: Models that replicate human metabolic conditions through controlled dietary interventions.

AI-Driven Capabilities

While Physiogenex employs advanced technologies in its research, specific AI-driven capabilities are not detailed in the available information.

Leadership Team

Executive Profiles

• Thierry Sulpice, Ph.D.

CEO, CSO, Founder, Member of the Scientific Advisory Board
Dr. Sulpice has over 20 years of experience in metabolic diseases research. Prior to founding Physiogenex, he was a Research Scientist and Head of the Cardiovascular and Metabolic Diseases Unit at Sanofi-Aventis. He holds a Ph.D. in Physiology and Pharmacology from the University of Grenoble, France.

• François Briand, Ph.D.

Director of Research and Business Development, Member of the Scientific Advisory Board
Dr. Briand has been an expert in metabolic diseases since 2007, focusing on the development of novel in vivo assays and animal models. He earned his Ph.D. in Nutrition and Metabolism from the University of Nantes, France.

• Estelle Grasset, Ph.D.

Project Manager - Research & Development
Dr. Grasset earned her Ph.D. in Immunology from the Federal University of Minas Gerais, Brazil, in 2010. She has extensive experience in developing in vitro and in vivo models to study metabolic disorders.

• Natália Breyner, Ph.D.

Project Manager - Research & Development
Dr. Breyner holds a Ph.D. in Immunology from the Federal University of Minas Gerais, Brazil. She has worked on the interaction of the intestinal microbiota with the host and immunological aspects of metabolic diseases.

• Claire Bigot

Research Scientist – Business Developer
Ms. Bigot is a Pharmacist with a Ph.D. in Immunology from the University of Toulouse III and a Master’s in Management from Toulouse Business School. She has experience in scientific training and stability analysis in the pharmaceutical industry.

Leadership Changes

In 2025, Estelle Grasset, Ph.D., was appointed Head of Scientific Operations at Physiogenex. In this role, she oversees the coordination and scientific quality of all studies conducted at the company.

Market and Competitor Insights

Market Dynamics

The preclinical CRO market for metabolic diseases is expanding rapidly due to the increasing global prevalence of related disorders. Companies such as Physiogenex are strategically positioned to address this rising demand by offering specialized services tailored to the pharmaceutical and biotechnology sectors.

Competitor Landscape

Specific competitors are not enumerated in the available information. The market includes multiple players specializing in metabolic diseases. Physiogenex distinguishes itself through its extensive experience, innovative animal models, and strong customer satisfaction.

Strategic Collaborations and Partnerships

• Vaiomer: In April 2023, Physiogenex and Vaiomer launched the TRANSBIOTIC project, a three-year research initiative to develop mouse models transplanted with human microbiome for evaluating therapies targeting intestinal, liver, and inflammatory diseases.

• Aiosyn: In March 2024, Physiogenex partnered with Aiosyn, a medical software company specializing in AI-powered pathology solutions, to enhance kidney disease drug development.

Operational Insights

Physiogenex's strategic collaborations with Vaiomer and Aiosyn enhance its market position by integrating advanced technologies and expanding its portfolio of preclinical services. These partnerships enable comprehensive approaches to drug development challenges in metabolic diseases.

Strategic Opportunities

Physiogenex is well-positioned to leverage its expertise and collaborations to broaden its service offerings and enter new market segments. The company’s focus on innovation and customer satisfaction lays a strong foundation for growth within the preclinical CRO sector.